Clifford Chance advises Sirnaomics on its Chapter 18A Hong Kong IPO and listing
30 December 2021
- Liu Fang, Virginia Lee, Daryl Fairbairn (He/Him), , Erxin Lu, , , ,
- Hong Kong, Beijing, Shanghai, New York
Clifford Chance advises Sirnaomics on its Chapter 18A Hong Kong IPO and listing
Leading international law firm Clifford Chance has advised biotech firm Sirnaomics Ltd's US$63.7 million initial public offering (IPO) and listing on the mainboard of the Hong Kong Stock Exchange.
Sirnaomics is the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics and the first clinical-stage RNA therapeutics company to have a strong presence in both China and the U.S. The product pipeline of Sirnaomics has over a dozen product candidates for a range of therapeutic indications across rare and large market diseases and its product candidates currently span all stages between preclinical research and IND-enabling studies to Phase I and Phase II clinical trials, creating an extended timeline of product candidates.
The transaction was led by Hong Kong partners Fang Liu and Virginia Lee, supported by a cross-border team from China and the US. Team members include counsel Daryl Fairbairn and associate Jennifer Saionz in New York, senior associate Erxin Lu, associate Ada Zheng and trainee Ruonan Tang in Beijing, counsel Samson Chan and trainee Irene Lau in Shanghai, and associates Jason Liu and Yuan Cao in Hong Kong.
Partner Fang Liu said, "We are pleased to have advised Sirnaomics on this exciting Chapter 18A IPO and listing, being the first RNA therapeutics company to be listed in Hong Kong."
高伟绅客户生物科技公司圣诺医药完成6370万美元首次公开发行和香港上市
国际领先律师事务所高伟绅为圣诺医药6,370万美元首次公开发行和香港联交所主板上市提供法律服务。
圣诺医药是首家就RNAi1疗法在肿瘤学领域取得积极IIa期临床结果的公司,且是首家在中国和美国均占有重要市场地位的临床阶段RNA疗法公司。圣诺医药目前产品线共有十多种候选产品,适用于罕见及患者人数众多的疾病等一系列治疗适应症,覆盖肿瘤、纤维化、抗病毒、代谢疾病等领域。
本交易由香港办公室合伙人方刘和李婉雯领导,由纽约办公室Daryl Fairbairn和Jennifer Saionz、北京办公室陆尔馨、郑喻丹和唐若楠、上海办公室陈澍森和刘嘉怡以及香港办公室廖进仁和曹嫄组成的跨国团队提供支持。
本交易由香港办公室合伙人方刘和李婉雯领导,由纽约办公室Daryl Fairbairn和Jennifer Saionz、北京办公室陆尔馨、郑喻丹和唐若楠、上海办公室陈澍森和刘嘉怡以及香港办公室廖进仁和曹嫄组成的跨国团队提供支持。
方律师表示:“我们非常高兴协助圣诺医药达成第18A章上市,成为首家登陆香港资本市场的RNA疗法公司。”
注释1:RNAi指RNA干扰,即RNA分子通过翻译或转录抑制参与双链RNA对基因表达的序列特异性抑制的生物学过程。